Floatz logo

Antibody Drug Conjugate Composed Of A Humanized Monoclonal Antibody Targeting Cldn18.2 And Linker-Payload Mc-Vc-Pab-Mmae

Chemotherapy-Induced Toxicity

Explore 63 assets in Chemotherapy-Induced Toxicity →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
Shanghai Zhongshan Hospital
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07108504CT.gov
Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer
—Not Yet Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Chemotherapy-Induced Toxicity

AssetSponsorPhaseRating
Antibody Drug Conjugate Composed Of A Humanized Monoclonal Antibody Targeting Cldn18.2 And Linker-Payload Mc-Vc-Pab-Mmae (this asset)Shanghai Zhongshan HospitalP2CCC · 53
PalonosetronSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityP4A
DexasoneInstituto do Cancer do Estado de São PauloP4A
Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-Second Affiliated Hospital, School of Medicine, Zhejiang UniversityP4BBB
NetupitantInstituto Brasileiro de Controle do CancerP3BB
DocetaxelThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolP4BB
HR20013Fujian Shengdi Pharmaceutical Co., Ltd.P3BB
CarboplatinEndeavor HealthP3BB
OndansetronDr Atul SharmaP3BB

+42 more in the Chemotherapy-Induced Toxicity cohort

Other indications for Antibody Drug Conjugate Composed Of A Humanized Monoclonal Antibody Targeting Cldn18.2 And Linker-Payload Mc-Vc-Pab-Mmae

IndicationSponsorPhaseRating
Cancer—P1/2CCC · 55
Pancreatic Neoplasm—P2CC · 46

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Antibody Drug Conjugate Composed Of A Humanized Monoclonal Antibody Targeting Cldn18.2 And Linker-Payload Mc-Vc-Pab-Mmae in Chemotherapy-Induced Toxicity. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/antibody-drug-conjugate-composed-of-a-humanized-monoclonal-antibody-targeting-cldn182-and-linker-payload-mc-vc-pab-mmae-chemotherapy-induced-toxicity

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →